PERCEVAL: CT Scan Sizing for Perceval Sutureless Valve

Sponsor
Maria Cecilia Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05799573
Collaborator
(none)
50
1
24
2.1

Study Details

Study Description

Brief Summary

The Perceval sutureless aortic bioprosthesis is a bovine pericardium valve mounted in a nitinol stent that can be compressed and positioned in a valve delivery system. Similarly, to transcatheter aortic valve implantation (TAVI) devices, the anchoring and good sealing of the Perceval bioprosthesis relies on oversizing by design of the nitinol stent compared with the native aortic annulus. With the advent of TAVI, cardiac computed tomography (CT) has become the gold standard technique for measuring the aortic annulus in patients undergoing transcatheter procedures, and the CT-derived axial image of the aortic virtual basal ring (VBR) is considered as the reference for sizing by most of the manufacturers of transcatheter valves .

Interestingly, the VBR lies exactly on the plane passing through the nadir of the 3 aortic cusps, that is where, according to the instructions for use, a correctly positioned Perceval valve should be deployed. VBR could then provide a good estimate of the annular dimension for the Perceval pre-operative sizing.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Recent evidence in TAVI patients suggests that significant underexpansion or distortion of valved stents may be associated with altered leaflet function, leading to increased transprosthetic gradients and possibly predisposing to other negative outcomes such as valve thrombosis, low platelet counts, thromboembolic events, and early degeneration . Moreover, there is evidence that excessive oversizing of the Perceval valve is detrimental.

    The present study is aimed to investigate the relationship between the CT-derived measure of the annulus dimension and early hemodynamic and clinical outcomes in patients undergoing sutureless aortic valve replacement (AVR) with the Perceval sutureless aortic valve and define the Perceval sizing chart based on preoperative CT-scan measurements.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    CT-scan Sizing Perceval Sutureless Valve
    Actual Study Start Date :
    Dec 1, 2022
    Anticipated Primary Completion Date :
    Dec 1, 2023
    Anticipated Study Completion Date :
    Dec 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Evaluate the proper Perceval valve size assessed by the early postoperative outcomes at discharge [12 months]

      The primary endpoint is to evaluate the proper Perceval valve size assessed by the early postoperative outcomes at discharge in terms of: Mean and peak pressure gradients Prosthetic regurgitation migration/dislodgement need for permanent pacemaker implant

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    1. Male and female subjects > 18 years;

    2. Subjects willing to sign and date an informed consent for treatment of personal data;

    3. Subjects willing and able to comply with the follow up schedule of the protocol;

    4. Subjects with indication for aortic valve replacement on a tricuspid aortic valve;

    5. Subjects with possibly associated need for coronary revascularization.

    6. Subjects with Ejection Fraction ≥ 40%

    Exclusion Criteria:
    1. Male and female subjects ≤ 18 years;

    2. Subjects with bicuspid aortic valve

    3. Subjects with associated mitral valvulopathy or ascending aorta aneurysm

    4. Subjects with pure aortic insufficiency

    5. Subjects with Ejection Fraction < 40%

    6. Subjects with acute myocardial infarction < 30 gg

    7. Subjects with serum creatinine > 2 mg/Dl

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Maria Cecilia Hospital Cotignola Ravenna Italy 48033

    Sponsors and Collaborators

    • Maria Cecilia Hospital

    Investigators

    • Principal Investigator: Elisa Mikus, MD, Maria Cecilia Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Maria Cecilia Hospital
    ClinicalTrials.gov Identifier:
    NCT05799573
    Other Study ID Numbers:
    • PERCEVAL
    First Posted:
    Apr 5, 2023
    Last Update Posted:
    Apr 5, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 5, 2023